Meriofert Pfs (Follicle-Stimulating Hormone, Luteinising Hormone)

The FSH component binds to FSH receptors on ovarian granulosa cells, promoting follicle growth and estradiol production. The LH component binds to LH receptors on theca and luteal cells, stimulating androgen conversion to estrogen and supporting luteal phase function. Together they coordinate the hormonal cascade required for follicular maturation and ovulation.

The dose of Meriofert Pfs is individualized by the prescribing specialist based on the patient’s clinical profile, ovarian response monitoring, and treatment protocol. The prescriber determines the amount, frequency, and duration of administration to achieve the desired therapeutic outcome.

Meriofert Pfs is intended for use before pregnancy to achieve ovulation. Its safety in established pregnancy has not been established, and it is not recommended for use during pregnancy. Limited data are available for breastfeeding; therefore, the product should be used only if the potential benefit justifies any possible risk to the infant.

To order Meriofert Pfs, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Meriofert Pfs combines both FSH and LH activity in a single injectable, which can simplify dosing compared with regimens that require separate FSH and LH products. Some alternatives provide only FSH, requiring an additional LH or hCG injection for luteal support. The combined formulation may reduce injection burden while delivering comparable efficacy when used according to protocol.

Meriofert Pfs must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product is inadvertently exposed to temperatures outside this range, discard it and obtain a new supply.

Meriofert Pfs is administered by a qualified healthcare professional via intramuscular or subcutaneous injection, typically into the thigh or abdomen. The injection site should be rotated according to standard clinical practice, and the dose is prepared under aseptic conditions using sterile technique.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can be severe and require hospitalization, and rare thromboembolic events. Patients should be monitored closely for abdominal distension, rapid weight gain, shortness of breath, or severe pain, and immediate medical attention should be sought if these symptoms develop.

Meriofert Pfs should not be used in individuals with known hypersensitivity to any component of the formulation, in patients with active ovarian cysts, uncontrolled thyroid disease, or a history of severe OHSS. It is also contraindicated in women who are already pregnant.